Ryan D. Gentzler
About
Ryan D. Gentzler is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology.
According to data from OpenAlex, Ryan D. Gentzler has authored 86 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 67 papers in Oncology, 58 papers in Pulmonary and Respiratory Medicine and 10 papers in Molecular Biology. Recurrent topics in Ryan D. Gentzler's work include Lung Cancer Treatments and Mutations (46 papers), Cancer Immunotherapy and Biomarkers (35 papers) and Lung Cancer Research Studies (25 papers). Ryan D. Gentzler is often cited by papers focused on Lung Cancer Treatments and Mutations (46 papers), Cancer Immunotherapy and Biomarkers (35 papers) and Lung Cancer Research Studies (25 papers). Ryan D. Gentzler collaborates with scholars based in United States, Taiwan and Spain. Ryan D. Gentzler's co-authors include Shadia I. Jalal, Lecia V. Sequist, Hossein Borghaei, Shirish M. Gadgeel, James Chih‐Hsin Yang, Corey J. Langer, Matthew A. Gubens, Amita Patnaik, James Stevenson and Mark M. Awad and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer.
In The Last Decade
Ryan D. Gentzler
84 papers receiving 2.5k citations
Hit Papers
Peers
Ryan D. Gentzler
Maen Hussein United States
Shelley Coleman United States
Alexander I. Spira United States
Michael McCleod United States
Kristen A. Marrone United States
Jerome H. Goldschmidt United States
C. Lewanski United Kingdom
Leila Khoja United Kingdom
Sophie Cousin France
Diego Signorelli Italy
Citations per year, relative to Ryan D. Gentzler Ryan D. Gentzler (= 1×)
peers
Maen Hussein
Countries citing papers authored by Ryan D. Gentzler
Since
Specialization
Citations
This map shows the geographic impact of Ryan D. Gentzler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ryan D. Gentzler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ryan D. Gentzler more than expected).
Fields of papers citing papers by Ryan D. Gentzler
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Ryan D. Gentzler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ryan D. Gentzler. The network helps show where Ryan D. Gentzler may publish in the future.
Co-authorship network of co-authors of Ryan D. Gentzler
This figure shows the co-authorship network connecting the top 25 collaborators of Ryan D. Gentzler. A scholar is included among the top collaborators of Ryan D. Gentzler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ryan D. Gentzler. Ryan D. Gentzler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Dougherty, Sean C., et al.. (2025). Real-World Outcomes of Tarlatamab in Small Cell Lung Cancer, Including Patients With Untreated Brain Metastases. Clinical Lung Cancer. 26(5). 347–353.e1.
2.
Saunders, E. Fred, Edward B. Stelow, Anne M. Mills, et al.. (2025). 1729 Clinicopathologic Characteristics and Potential Immunotherapeutic Implications of Lung Non-Small Cell Carcinomas with NOTCH Loss-of-Function Mutations. Laboratory Investigation. 105(3). 103974–103974.
3.
Dougherty, Sean C., et al.. (2025). Successful Treatment of Innumerable Untreated Brain Metastases With Trastuzumab Deruxtecan in Chemotherapy‐Naïve HER2‐Mutated Non‐Small‐Cell Lung Cancer. Case Reports in Oncological Medicine. 2025(1). 9936011–9936011.
4.
Cooper, Alissa J., et al.. (2024). First Report of Response to Tarlatamab in a Patient With DLL3-Positive Pulmonary Carcinoid: Case Report. JTO Clinical and Research Reports. 5(12). 100750–100750.
5.
Neal, Joel W., Armando Santoro, María González‐Cao, et al.. (2024). Cabozantinib Plus Atezolizumab or Cabozantinib Alone in Patients With Advanced NSCLC Previously Treated With an Immune Checkpoint Inhibitor: Results From the Phase 1b COSMIC-021 Study. JTO Clinical and Research Reports. 5(10). 100666–100666.
6.
Califano, Raffaele, SH Lee, Yuzhuo Wang, et al.. (2024). LBA54 Amivantamab plus chemotherapy vs chemotherapy in EGFR-mutated, advanced non-small cell lung cancer after disease progression on osimertinib: Second interim overall survival from MARIPOSA-2. Annals of Oncology. 35. S1244–S1245.
7.
Mamdani, Hirva, Seongho Kim, Ryan D. Gentzler, et al.. (2024). A phase II trial of monalizumab in combination with durvalumab (MEDI4736) plus platinum-based chemotherapy for first-line treatment of extensive stage small cell lung cancer (MOZART): Hoosier Cancer Research Network LUN21-530 study.. Journal of Clinical Oncology. 42(16_suppl). TPS8129–TPS8129.
8.
Owonikoko, Taofeek K., Alberto Chiappori, Ryan D. Gentzler, et al.. (2024). Alisertib in patients with extensive-stage small-cell lung cancer: The phase 2 ALISCA-Lung1 study.. Journal of Clinical Oncology. 42(16_suppl). TPS8128–TPS8128.
9.
Obeid, Joseph M., Ileana S. Mauldin, Ryan D. Gentzler, et al.. (2024). Spatial colocalization and combined survival benefit of natural killer and CD8 T cells despite profound MHC class I loss in non-small cell lung cancer. Journal for ImmunoTherapy of Cancer. 12(9). e009126–e009126.
10.
Young, Philip, et al.. (2024). Impact of Opioid Use on Duration of Therapy and Overall Survival for Patients with Advanced Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors. Current Oncology. 31(1). 260–273.
11.
Passaro, Antonio, Byoung Chul Cho, Yan Wang, et al.. (2023). LBA15 Amivantamab plus chemotherapy (with or without lazertinib) vs chemotherapy in EGFR-mutated advanced NSCLC after progression on osimertinib: MARIPOSA-2, a phase III, global, randomized, controlled trial. Annals of Oncology. 34. S1307–S1307.
12.
Gentzler, Ryan D., Liza C. Villaruz, John C. Rhee, et al.. (2023). Phase I Study of Entinostat, Atezolizumab, Carboplatin, and Etoposide in Previously Untreated Extensive-Stage Small Cell Lung Cancer, ETCTN 10399. The Oncologist. 28(11). 1007–e1107.
13.
Fadul, Camilo E., Joseph Bovi, Alissa A. Thomas, et al.. (2023). Relevance of the Updated Recursive Partitioning Analysis (U-RPA) Classification in the Contemporary Care of Patients with Brain Metastases. Cancers. 15(12). 3255–3255.
14.
Althouse, Sandra K., Ticiana Leal, Lawrence Feldman, et al.. (2022). A Phase II Trial of Atezolizumab Plus Carboplatin Plus Pemetrexed Plus Bevacizumab in the Treatment of Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer: Big Ten Cancer Research Consortium (BTCRC)- LUN 17-139. Clinical Lung Cancer. 23(7). 578–584.
15.
Young, Patrick, et al.. (2021). MO01.12 Association of Opioid Use with Survival in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitor Therapy. Journal of Thoracic Oncology. 16(1). S20–S21.
16.
Bertino, Erin M., Ryan D. Gentzler, Jill Kolesar, et al.. (2020). Phase IB Study of Osimertinib in Combination with Navitoclax in EGFR-mutant NSCLC Following Resistance to Initial EGFR Therapy (ETCTN 9903). Clinical Cancer Research. 27(6). 1604–1611.
17.
Durm, Greg Andrew, Salma K. Jabbour, Sandra K. Althouse, et al.. (2020). A phase 2 trial of consolidation pembrolizumab following concurrent chemoradiation for patients with unresectable stage III non–small cell lung cancer: Hoosier Cancer Research Network LUN 14‐179. Cancer. 126(19). 4353–4361.
18.
Dutta, Sunil W., Marie Mack, Eric Aliotta, et al.. (2020). Intracranial disease control for EGFR-mutant and ALK-rearranged lung cancer with large volume or symptomatic brain metastases. Journal of Neuro-Oncology. 149(2). 357–366.
19.
Durm, Greg Andrew, Sandra K. Althouse, Salma K. Jabbour, et al.. (2019). P1.18-05 ChemoXRT W/ Consolidation Pembrolizumab in Unresectable Stage III NSCLC: Long-Term Survival Update and Analysis of Post-Progression Therapy. Journal of Thoracic Oncology. 14(10). S627–S627.
20.
Borghaei, Hossein, Corey J. Langer, Shirish M. Gadgeel, et al.. (2018). 24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non–Small Cell Lung Cancer. Journal of Thoracic Oncology. 14(1). 124–129.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Maen Hussein Breakdown of academic impact, for papers by Shelley Coleman Breakdown of academic impact, for papers by Alexander I. Spira Breakdown of academic impact, for papers by Michael McCleod Breakdown of academic impact, for papers by Kristen A. Marrone Breakdown of academic impact, for papers by Jerome H. Goldschmidt Breakdown of academic impact, for papers by C. Lewanski Breakdown of academic impact, for papers by Leila Khoja Breakdown of academic impact, for papers by Sophie Cousin Breakdown of academic impact, for papers by Diego Signorelli